Abstract
PurposeThis study aimed to evaluate the neuroprotective effect of EPO in the presence of N-methyl-d-aspartate (NMDA)-, trophic factor withdrawal (TFW)-, and tumor necrosis factor-alpha (TNF-α)-induced toxicity on total, small, and large retinal ganglion cells (RGCs).MethodsRetinal cells from adult rats were cultured in a medium containing brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF), and forskolin. Expression of RGC markers and EPOR was examined using immunocytochemistry. RGCs were classified according to their morphological properties. Cytotoxicity was induced by NMDA, TFW, or TNF-α. RGC survival was assessed by counting thy-1 and neurofilament-l double-positive cells.ResultsEPO offered dose-dependent (EC50 = 5.7 ng/mL) protection against NMDA toxicity for small RGCs; protection was not significant for large RGCs. Time-course analysis showed that the presence of EPO either before or after NMDA exposure gave effective protection. For both small and large RGCs undergoing trophic factor withdrawal, EPO at concentrations of 1, 10, or 100 ng/mL improved survival. However, EPO had to be administered soon after the onset of injury to provide effective protection. For TNF-α-induced toxicity, survival of small RGCs was seen only for the highest examined concentration (100 ng/mL) of EPO, whereas large RGCs were protected at concentrations of 1, 10, or 100 ng/mL of EPO. Time-course analysis showed that pretreatment with EPO provided protection only for large RGCs; early post-treatment with EPO protected both small and large RGCs. Inhibitors of signal transduction and activators of transcription such as (STAT)-5, mitogen-activated protein kinases (MAPK)/extracellular-regulated kinase (ERK), and phosphatidyl inositol-3 kinase (PI3K)/Akt impaired the protective effect of EPO on RGCs exposed to different insults.ConclusionEPO provided neuroprotection to cultured adult rat RGCs; however, the degree of protection varied with the type of toxic insult, RGC subtype, and timing of EPO treatment.
Highlights
Glaucoma is the second leading cause of blindness in the world [1]
The present study aimed to evaluate the neuroprotective effects of EPO on total, small, and large retinal ganglion cells (RGCs) under N-methyl-Daspartate (NMDA), trophic factor withdrawal (TFW), and tumor necrosis factor-alpha (TNF-a)-induced toxicity in in vitro cultures of retinal cells
Identification and Morphology of Adult Rat RGCs In the mixed culture of retinal cells, RGCs were identified by retrograde labeling with FG, presence of specific markers, and cellular morphology
Summary
Glaucoma is the second leading cause of blindness in the world [1]. It is characterized by progressive death of retinal ganglion cells (RGCs) and visual field loss. Elevated intraocular pressure (IOP) is widely accepted as the major risk factor for glaucoma, RGC death and visual field loss continue to occur in some patients with good IOP control [2]. Neuroprotection, a method for preventing RGC death, has become a treatment strategy in glaucomatous optic neuropathy. There are no FDA-approved neuroprotectants for the treatment of glaucoma. This deficiency encourages further research into the potential application of neuroprotective treatments for glaucoma. An innovative approach is to use multifunctional neuroprotectants against the complex process of RGC death [10]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have